| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 16 | 2006 | 809 | 1.110 |
Why?
|
| Mercaptopurine | 6 | 2006 | 72 | 0.590 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 14 | 2006 | 1354 | 0.470 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2001 | 140 | 0.460 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2006 | 197 | 0.420 |
Why?
|
| Anemia, Iron-Deficiency | 2 | 2020 | 145 | 0.390 |
Why?
|
| Methotrexate | 8 | 2005 | 355 | 0.380 |
Why?
|
| Brain Neoplasms | 7 | 2008 | 1409 | 0.380 |
Why?
|
| Neutropenia | 3 | 2000 | 201 | 0.300 |
Why?
|
| Folic Acid Deficiency | 1 | 2008 | 55 | 0.300 |
Why?
|
| Vitamin B 12 Deficiency | 1 | 2008 | 45 | 0.300 |
Why?
|
| Anemia, Sickle Cell | 3 | 2005 | 341 | 0.300 |
Why?
|
| Radiotherapy, Conformal | 1 | 2008 | 63 | 0.290 |
Why?
|
| Medulloblastoma | 4 | 2008 | 570 | 0.290 |
Why?
|
| Child, Preschool | 38 | 2020 | 14800 | 0.280 |
Why?
|
| Carboplatin | 2 | 2000 | 87 | 0.260 |
Why?
|
| Radiation Injuries | 1 | 2008 | 165 | 0.260 |
Why?
|
| Iron | 3 | 2020 | 303 | 0.260 |
Why?
|
| Meningeal Neoplasms | 2 | 2008 | 220 | 0.260 |
Why?
|
| Meningioma | 1 | 2008 | 144 | 0.250 |
Why?
|
| Bone Marrow | 4 | 1998 | 335 | 0.250 |
Why?
|
| Leukemia, Lymphoid | 7 | 1988 | 110 | 0.250 |
Why?
|
| Hodgkin Disease | 3 | 1998 | 298 | 0.240 |
Why?
|
| Salvage Therapy | 1 | 2006 | 202 | 0.220 |
Why?
|
| Child | 41 | 2015 | 25739 | 0.200 |
Why?
|
| Chromosomes, Human, Pair 7 | 2 | 1996 | 78 | 0.200 |
Why?
|
| Infant | 24 | 2020 | 13161 | 0.200 |
Why?
|
| Pulmonary Artery | 1 | 2005 | 455 | 0.190 |
Why?
|
| Central Nervous System Diseases | 2 | 1998 | 110 | 0.190 |
Why?
|
| Myelodysplastic Syndromes | 2 | 1996 | 129 | 0.190 |
Why?
|
| Infusions, Intravenous | 5 | 2006 | 570 | 0.180 |
Why?
|
| Administration, Oral | 6 | 2020 | 730 | 0.180 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2001 | 29 | 0.180 |
Why?
|
| Hypertension, Pulmonary | 1 | 2005 | 467 | 0.170 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2001 | 136 | 0.170 |
Why?
|
| Optic Nerve Neoplasms | 1 | 2000 | 20 | 0.170 |
Why?
|
| Male | 44 | 2020 | 65881 | 0.170 |
Why?
|
| Splenectomy | 2 | 2012 | 63 | 0.170 |
Why?
|
| Humans | 67 | 2020 | 133931 | 0.170 |
Why?
|
| Multi-Institutional Systems | 1 | 2000 | 12 | 0.170 |
Why?
|
| Leukopenia | 1 | 2000 | 48 | 0.160 |
Why?
|
| Antineoplastic Agents | 5 | 2000 | 1850 | 0.160 |
Why?
|
| Nonprescription Drugs | 1 | 2000 | 51 | 0.160 |
Why?
|
| Zinc | 1 | 2000 | 141 | 0.160 |
Why?
|
| Critical Pathways | 1 | 2000 | 79 | 0.160 |
Why?
|
| Cytomegalovirus Infections | 1 | 2001 | 228 | 0.150 |
Why?
|
| Adolescent | 27 | 2012 | 20536 | 0.150 |
Why?
|
| Female | 41 | 2020 | 71658 | 0.150 |
Why?
|
| Program Development | 1 | 2000 | 190 | 0.150 |
Why?
|
| Autoimmune Diseases | 1 | 2001 | 279 | 0.150 |
Why?
|
| Thrombosis | 2 | 2015 | 537 | 0.140 |
Why?
|
| Ventricular Function, Left | 1 | 2001 | 544 | 0.140 |
Why?
|
| Glioma | 2 | 2000 | 537 | 0.140 |
Why?
|
| Gene Amplification | 1 | 1998 | 247 | 0.140 |
Why?
|
| Burkitt Lymphoma | 2 | 1998 | 142 | 0.130 |
Why?
|
| Heart | 1 | 2001 | 749 | 0.130 |
Why?
|
| Ganglioglioma | 1 | 1996 | 22 | 0.130 |
Why?
|
| Isochromosomes | 1 | 1996 | 18 | 0.130 |
Why?
|
| Anemia | 1 | 2000 | 351 | 0.130 |
Why?
|
| Remission Induction | 7 | 1998 | 308 | 0.120 |
Why?
|
| Leukemia, Myelomonocytic, Juvenile | 1 | 2015 | 11 | 0.120 |
Why?
|
| Combined Modality Therapy | 7 | 2012 | 1315 | 0.120 |
Why?
|
| Chromosome Aberrations | 2 | 1998 | 626 | 0.120 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 2 | 2012 | 50 | 0.120 |
Why?
|
| Antithrombin III | 1 | 2015 | 26 | 0.120 |
Why?
|
| Anemia, Hemolytic, Congenital Nonspherocytic | 1 | 1995 | 3 | 0.120 |
Why?
|
| Pyruvate Kinase | 1 | 1995 | 11 | 0.120 |
Why?
|
| Bone Marrow Transplantation | 2 | 1996 | 621 | 0.120 |
Why?
|
| Mediastinal Cyst | 1 | 1994 | 10 | 0.120 |
Why?
|
| Mediastinal Diseases | 1 | 1994 | 15 | 0.120 |
Why?
|
| Hospitals, Pediatric | 1 | 2000 | 789 | 0.120 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 1995 | 74 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2006 | 1315 | 0.110 |
Why?
|
| Disease-Free Survival | 4 | 2015 | 971 | 0.110 |
Why?
|
| Bronchiolitis | 1 | 1995 | 123 | 0.110 |
Why?
|
| Isoenzymes | 1 | 1995 | 231 | 0.110 |
Why?
|
| Parvovirus | 1 | 1993 | 8 | 0.110 |
Why?
|
| Heparin | 1 | 2015 | 226 | 0.110 |
Why?
|
| Parvoviridae Infections | 1 | 1993 | 36 | 0.110 |
Why?
|
| Lymphocytes | 1 | 1995 | 440 | 0.110 |
Why?
|
| Panniculitis | 1 | 1993 | 19 | 0.100 |
Why?
|
| Abscess | 1 | 1994 | 141 | 0.100 |
Why?
|
| Purpura | 1 | 1993 | 26 | 0.100 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 1995 | 224 | 0.100 |
Why?
|
| Hematoma | 1 | 1993 | 94 | 0.100 |
Why?
|
| Diagnosis, Differential | 4 | 2008 | 1977 | 0.100 |
Why?
|
| Haemophilus Vaccines | 1 | 1992 | 30 | 0.100 |
Why?
|
| Organoplatinum Compounds | 1 | 1992 | 34 | 0.100 |
Why?
|
| Tetanus Toxoid | 1 | 1992 | 48 | 0.100 |
Why?
|
| Acute Disease | 5 | 2015 | 1189 | 0.090 |
Why?
|
| Bacterial Vaccines | 1 | 1992 | 102 | 0.090 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 1995 | 366 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 9 | 2009 | 2196 | 0.090 |
Why?
|
| Haemophilus Infections | 1 | 1992 | 95 | 0.090 |
Why?
|
| Haemophilus influenzae | 1 | 1992 | 134 | 0.090 |
Why?
|
| Splenic Infarction | 1 | 1991 | 4 | 0.090 |
Why?
|
| Protein C Deficiency | 1 | 1991 | 12 | 0.090 |
Why?
|
| Proportional Hazards Models | 3 | 2000 | 1483 | 0.090 |
Why?
|
| Mutation | 2 | 2015 | 6297 | 0.090 |
Why?
|
| Mesenteric Vascular Occlusion | 1 | 1991 | 28 | 0.090 |
Why?
|
| Drug Administration Schedule | 4 | 2000 | 755 | 0.090 |
Why?
|
| Anticoagulants | 1 | 2015 | 598 | 0.080 |
Why?
|
| Survival Rate | 5 | 2005 | 2207 | 0.080 |
Why?
|
| Thalassemia | 1 | 2010 | 11 | 0.080 |
Why?
|
| Antibodies, Bacterial | 1 | 1992 | 404 | 0.080 |
Why?
|
| Chlorambucil | 1 | 1989 | 6 | 0.080 |
Why?
|
| Purpura, Thrombocytopenic | 1 | 1988 | 7 | 0.080 |
Why?
|
| gamma-Globulins | 1 | 1988 | 6 | 0.080 |
Why?
|
| Injections, Spinal | 4 | 1998 | 136 | 0.080 |
Why?
|
| Health Care Costs | 1 | 2012 | 404 | 0.080 |
Why?
|
| Vitamin B 12 | 1 | 2008 | 63 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 1989 | 100 | 0.070 |
Why?
|
| Leukemia, Myeloid, Acute | 4 | 1990 | 569 | 0.070 |
Why?
|
| von Willebrand Diseases | 1 | 2009 | 52 | 0.070 |
Why?
|
| Survival Analysis | 4 | 2000 | 1596 | 0.070 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2010 | 234 | 0.070 |
Why?
|
| Antidotes | 2 | 1998 | 14 | 0.070 |
Why?
|
| Blood Cell Count | 2 | 2000 | 70 | 0.070 |
Why?
|
| Leucovorin | 2 | 1998 | 54 | 0.070 |
Why?
|
| Bone Neoplasms | 2 | 1986 | 447 | 0.070 |
Why?
|
| Agranulocytosis | 1 | 1987 | 13 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2010 | 3849 | 0.070 |
Why?
|
| Genome-Wide Association Study | 1 | 2015 | 1870 | 0.070 |
Why?
|
| Glycogen Storage Disease Type I | 1 | 1987 | 11 | 0.070 |
Why?
|
| Adult | 10 | 2020 | 31946 | 0.070 |
Why?
|
| Wilms Tumor | 1 | 2009 | 119 | 0.070 |
Why?
|
| Lithium | 1 | 1987 | 71 | 0.070 |
Why?
|
| Skin Diseases | 1 | 1989 | 135 | 0.070 |
Why?
|
| Nutrition Surveys | 1 | 2008 | 312 | 0.070 |
Why?
|
| Laparoscopy | 1 | 2012 | 513 | 0.070 |
Why?
|
| Sex Factors | 4 | 2000 | 1384 | 0.070 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 1989 | 214 | 0.070 |
Why?
|
| Karyotyping | 2 | 1998 | 324 | 0.070 |
Why?
|
| Folic Acid | 1 | 2008 | 298 | 0.060 |
Why?
|
| Staphylococcal Infections | 2 | 2006 | 573 | 0.060 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 1989 | 239 | 0.060 |
Why?
|
| Chromosome Deletion | 1 | 1989 | 664 | 0.060 |
Why?
|
| Polyglutamic Acid | 1 | 2005 | 3 | 0.060 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2005 | 113 | 0.060 |
Why?
|
| Follow-Up Studies | 4 | 2005 | 5505 | 0.060 |
Why?
|
| Vincristine | 4 | 1995 | 196 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2010 | 2162 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 3475 | 0.060 |
Why?
|
| Prognosis | 5 | 2015 | 5074 | 0.060 |
Why?
|
| Venous Thrombosis | 1 | 2006 | 169 | 0.060 |
Why?
|
| Hearing Loss, High-Frequency | 1 | 1983 | 1 | 0.050 |
Why?
|
| Myelin Basic Protein | 1 | 1984 | 69 | 0.050 |
Why?
|
| Treatment Outcome | 6 | 2005 | 13011 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2005 | 5173 | 0.050 |
Why?
|
| Osteomyelitis | 1 | 2006 | 211 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2015 | 4900 | 0.050 |
Why?
|
| Prednisone | 5 | 1995 | 289 | 0.050 |
Why?
|
| Algorithms | 1 | 2010 | 1735 | 0.050 |
Why?
|
| Staphylococcus aureus | 1 | 2006 | 476 | 0.050 |
Why?
|
| Leukocyte Count | 2 | 2000 | 259 | 0.050 |
Why?
|
| Cisplatin | 1 | 1983 | 287 | 0.050 |
Why?
|
| Disease Progression | 2 | 2015 | 2239 | 0.050 |
Why?
|
| Prevalence | 1 | 2008 | 2654 | 0.050 |
Why?
|
| Coombs Test | 1 | 2001 | 6 | 0.050 |
Why?
|
| Immune Sera | 1 | 2001 | 95 | 0.050 |
Why?
|
| Cerebellar Neoplasms | 1 | 1986 | 461 | 0.050 |
Why?
|
| Neoplasm Metastasis | 2 | 1981 | 746 | 0.050 |
Why?
|
| Hearing Loss | 1 | 1983 | 214 | 0.050 |
Why?
|
| Urine | 1 | 2001 | 83 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2006 | 1201 | 0.040 |
Why?
|
| Pilot Projects | 2 | 1996 | 1485 | 0.040 |
Why?
|
| Nasopharynx | 1 | 2001 | 86 | 0.040 |
Why?
|
| Methylprednisolone | 1 | 2001 | 104 | 0.040 |
Why?
|
| Immunization, Passive | 1 | 2001 | 128 | 0.040 |
Why?
|
| Monocytes | 1 | 1983 | 361 | 0.040 |
Why?
|
| Self Medication | 1 | 2000 | 22 | 0.040 |
Why?
|
| Acne Vulgaris | 1 | 2000 | 24 | 0.040 |
Why?
|
| Oncology Nursing | 1 | 2000 | 10 | 0.040 |
Why?
|
| Ploidies | 1 | 2000 | 38 | 0.040 |
Why?
|
| Copper | 1 | 2000 | 75 | 0.040 |
Why?
|
| Pediatric Nursing | 1 | 2000 | 25 | 0.040 |
Why?
|
| Cytomegalovirus | 1 | 2001 | 271 | 0.040 |
Why?
|
| Risk Factors | 2 | 2008 | 11086 | 0.040 |
Why?
|
| Base Sequence | 2 | 1995 | 3171 | 0.040 |
Why?
|
| Electroencephalography | 2 | 1981 | 905 | 0.040 |
Why?
|
| Aspergillosis | 1 | 1979 | 47 | 0.040 |
Why?
|
| Leukemia | 2 | 1990 | 380 | 0.040 |
Why?
|
| Treatment Failure | 2 | 1998 | 363 | 0.040 |
Why?
|
| Molecular Sequence Data | 2 | 1995 | 3970 | 0.040 |
Why?
|
| Recurrence | 2 | 1993 | 1471 | 0.040 |
Why?
|
| Chronic Disease | 3 | 2012 | 1253 | 0.040 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1979 | 72 | 0.040 |
Why?
|
| Cooperative Behavior | 1 | 2000 | 233 | 0.040 |
Why?
|
| Brain | 4 | 2001 | 3220 | 0.040 |
Why?
|
| Platelet Count | 3 | 2012 | 143 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2001 | 823 | 0.040 |
Why?
|
| B-Lymphocytes | 2 | 2005 | 550 | 0.040 |
Why?
|
| Ovarian Neoplasms | 1 | 1982 | 464 | 0.040 |
Why?
|
| Injections, Intramuscular | 2 | 1995 | 199 | 0.040 |
Why?
|
| Young Adult | 2 | 2010 | 9887 | 0.040 |
Why?
|
| Herpesviridae Infections | 2 | 1989 | 147 | 0.030 |
Why?
|
| Disease Outbreaks | 1 | 1979 | 330 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2005 | 563 | 0.030 |
Why?
|
| Neoplasms | 1 | 1992 | 3027 | 0.030 |
Why?
|
| Patient Selection | 1 | 2000 | 734 | 0.030 |
Why?
|
| Subarachnoid Space | 1 | 1996 | 25 | 0.030 |
Why?
|
| Monosomy | 1 | 1996 | 25 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 1998 | 791 | 0.030 |
Why?
|
| Melphalan | 1 | 1996 | 45 | 0.030 |
Why?
|
| Osteosarcoma | 1 | 1979 | 263 | 0.030 |
Why?
|
| Germinoma | 1 | 1996 | 32 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 1996 | 168 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1996 | 69 | 0.030 |
Why?
|
| Echocardiography | 1 | 2001 | 1124 | 0.030 |
Why?
|
| Leukemia, Myeloid | 1 | 2015 | 82 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 1996 | 286 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2000 | 573 | 0.030 |
Why?
|
| Partial Thromboplastin Time | 1 | 2015 | 48 | 0.030 |
Why?
|
| Asparaginase | 1 | 1995 | 48 | 0.030 |
Why?
|
| DNA, Satellite | 1 | 1995 | 16 | 0.030 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1995 | 73 | 0.030 |
Why?
|
| Antithrombins | 1 | 2015 | 57 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1996 | 401 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2001 | 1204 | 0.030 |
Why?
|
| Factor Xa Inhibitors | 1 | 2015 | 66 | 0.030 |
Why?
|
| Staphylococcus | 1 | 1994 | 68 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 648 | 0.030 |
Why?
|
| United States | 2 | 2000 | 11683 | 0.030 |
Why?
|
| Ependymoma | 1 | 1996 | 175 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 1996 | 321 | 0.030 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1995 | 372 | 0.030 |
Why?
|
| Retrospective Studies | 4 | 2012 | 17481 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 1998 | 1386 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 1996 | 418 | 0.030 |
Why?
|
| Age Factors | 2 | 2000 | 2977 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 1996 | 1124 | 0.030 |
Why?
|
| Haplotypes | 1 | 1995 | 562 | 0.030 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 1 | 1992 | 7 | 0.030 |
Why?
|
| Pons | 1 | 1993 | 35 | 0.020 |
Why?
|
| Rho(D) Immune Globulin | 1 | 2012 | 8 | 0.020 |
Why?
|
| Catheterization, Central Venous | 1 | 1994 | 135 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2020 | 6664 | 0.020 |
Why?
|
| Parents | 1 | 2020 | 1060 | 0.020 |
Why?
|
| Demyelinating Diseases | 1 | 1993 | 70 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 1995 | 838 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2012 | 341 | 0.020 |
Why?
|
| Pancytopenia | 1 | 1992 | 42 | 0.020 |
Why?
|
| Bites and Stings | 1 | 2012 | 28 | 0.020 |
Why?
|
| Pentosephosphates | 1 | 1992 | 9 | 0.020 |
Why?
|
| Isoantibodies | 1 | 2012 | 72 | 0.020 |
Why?
|
| Central Nervous System Neoplasms | 1 | 1995 | 216 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 1992 | 105 | 0.020 |
Why?
|
| Wound Infection | 1 | 2012 | 54 | 0.020 |
Why?
|
| Drug Costs | 1 | 2012 | 67 | 0.020 |
Why?
|
| Polysaccharides, Bacterial | 1 | 1992 | 70 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 1993 | 184 | 0.020 |
Why?
|
| DNA, Viral | 1 | 1993 | 499 | 0.020 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2012 | 148 | 0.020 |
Why?
|
| Interferon-alpha | 1 | 1993 | 248 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 1735 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 1995 | 896 | 0.020 |
Why?
|
| Dogs | 1 | 2012 | 800 | 0.020 |
Why?
|
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 1 | 1990 | 2 | 0.020 |
Why?
|
| Pyoderma | 1 | 1990 | 2 | 0.020 |
Why?
|
| Deficiency Diseases | 1 | 1991 | 11 | 0.020 |
Why?
|
| Hemiplegia | 1 | 1991 | 46 | 0.020 |
Why?
|
| Hospital Costs | 1 | 2012 | 187 | 0.020 |
Why?
|
| Pedigree | 1 | 1995 | 1694 | 0.020 |
Why?
|
| Neutrophils | 1 | 1993 | 401 | 0.020 |
Why?
|
| Ischemic Attack, Transient | 1 | 1991 | 64 | 0.020 |
Why?
|
| Thrombocythemia, Essential | 1 | 1991 | 30 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 1995 | 1418 | 0.020 |
Why?
|
| Neoplasms, Second Primary | 1 | 1992 | 164 | 0.020 |
Why?
|
| Mesenteric Arteries | 1 | 1991 | 56 | 0.020 |
Why?
|
| Autoantibodies | 1 | 1993 | 466 | 0.020 |
Why?
|
| Cecal Diseases | 1 | 1990 | 6 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 2012 | 304 | 0.020 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1992 | 128 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2015 | 1022 | 0.020 |
Why?
|
| Bacteremia | 1 | 1994 | 418 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 962 | 0.020 |
Why?
|
| Quinazolines | 1 | 1991 | 184 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 1993 | 1631 | 0.020 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1990 | 102 | 0.020 |
Why?
|
| Sarcoma | 1 | 1992 | 210 | 0.020 |
Why?
|
| Herpesvirus 4, Human | 2 | 1989 | 676 | 0.020 |
Why?
|
| Image Enhancement | 1 | 2010 | 170 | 0.020 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 1991 | 283 | 0.020 |
Why?
|
| Middle Aged | 1 | 2008 | 29394 | 0.020 |
Why?
|
| Necrosis | 2 | 1990 | 220 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2012 | 693 | 0.020 |
Why?
|
| Anemia, Aplastic | 1 | 1988 | 62 | 0.020 |
Why?
|
| Lithium Carbonate | 1 | 1987 | 21 | 0.020 |
Why?
|
| Neoplasms, Muscle Tissue | 1 | 1987 | 10 | 0.020 |
Why?
|
| Infant, Newborn | 4 | 2015 | 8592 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 1993 | 3167 | 0.020 |
Why?
|
| Thigh | 1 | 1987 | 53 | 0.020 |
Why?
|
| Ultrasonography | 2 | 1982 | 1002 | 0.020 |
Why?
|
| Kinetics | 1 | 2009 | 1355 | 0.020 |
Why?
|
| Methicillin Resistance | 1 | 2006 | 118 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 1988 | 567 | 0.020 |
Why?
|
| Bone Marrow Diseases | 1 | 1986 | 41 | 0.020 |
Why?
|
| Brain Diseases | 1 | 1988 | 311 | 0.010 |
Why?
|
| Bacterial Infections | 2 | 1990 | 325 | 0.010 |
Why?
|
| Community-Acquired Infections | 1 | 2006 | 247 | 0.010 |
Why?
|
| Pulmonary Embolism | 1 | 2006 | 186 | 0.010 |
Why?
|
| Mechlorethamine | 2 | 1993 | 8 | 0.010 |
Why?
|
| Procarbazine | 2 | 1993 | 12 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 3054 | 0.010 |
Why?
|
| Seizures | 1 | 1988 | 889 | 0.010 |
Why?
|
| Urography | 1 | 1981 | 31 | 0.010 |
Why?
|
| Phagocytosis | 1 | 1983 | 191 | 0.010 |
Why?
|
| Levamisole | 1 | 1981 | 4 | 0.010 |
Why?
|
| Lymphocyte Transfusion | 1 | 1981 | 58 | 0.010 |
Why?
|
| BCG Vaccine | 1 | 1981 | 110 | 0.010 |
Why?
|
| Biomarkers | 1 | 2010 | 3423 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2012 | 3226 | 0.010 |
Why?
|
| Air Movements | 1 | 1979 | 1 | 0.010 |
Why?
|
| Maintenance and Engineering, Hospital | 1 | 1979 | 1 | 0.010 |
Why?
|
| Air Conditioning | 1 | 1979 | 2 | 0.010 |
Why?
|
| Air Microbiology | 1 | 1979 | 12 | 0.010 |
Why?
|
| Testis | 1 | 1981 | 426 | 0.010 |
Why?
|
| Technetium | 1 | 1979 | 15 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1979 | 151 | 0.010 |
Why?
|
| Neuroblastoma | 1 | 1983 | 539 | 0.010 |
Why?
|
| Biopsy | 1 | 1981 | 1304 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 1998 | 317 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1981 | 644 | 0.010 |
Why?
|
| Texas | 2 | 1992 | 3689 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 1981 | 412 | 0.010 |
Why?
|
| Cross Infection | 1 | 1979 | 332 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 1981 | 1153 | 0.010 |
Why?
|
| Coagulase | 1 | 1994 | 23 | 0.010 |
Why?
|
| Electrophoresis | 1 | 1994 | 52 | 0.010 |
Why?
|
| Kidney | 1 | 1981 | 1410 | 0.010 |
Why?
|
| Liver | 1 | 1981 | 1875 | 0.010 |
Why?
|
| Teniposide | 1 | 1993 | 2 | 0.010 |
Why?
|
| Daunorubicin | 1 | 1993 | 27 | 0.010 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 1993 | 32 | 0.010 |
Why?
|
| Cytarabine | 1 | 1993 | 100 | 0.010 |
Why?
|
| Vinblastine | 1 | 1993 | 58 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1993 | 254 | 0.010 |
Why?
|
| Dacarbazine | 1 | 1993 | 99 | 0.010 |
Why?
|
| Bleomycin | 1 | 1993 | 153 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 1993 | 242 | 0.010 |
Why?
|
| Cranial Irradiation | 1 | 1992 | 72 | 0.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1993 | 244 | 0.010 |
Why?
|
| Doxorubicin | 1 | 1993 | 302 | 0.010 |
Why?
|
| Dysarthria | 1 | 1991 | 24 | 0.010 |
Why?
|
| Gangrene | 1 | 1990 | 27 | 0.010 |
Why?
|
| Mumps | 1 | 1970 | 12 | 0.010 |
Why?
|
| Animals | 1 | 2012 | 36398 | 0.010 |
Why?
|
| Environment, Controlled | 1 | 1990 | 8 | 0.010 |
Why?
|
| Patient Isolation | 1 | 1990 | 15 | 0.010 |
Why?
|
| Filtration | 1 | 1990 | 24 | 0.010 |
Why?
|
| Whole-Body Irradiation | 1 | 1990 | 61 | 0.010 |
Why?
|
| Autopsy | 1 | 1990 | 119 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1993 | 1439 | 0.010 |
Why?
|
| Aspirin | 1 | 1991 | 231 | 0.000 |
Why?
|
| Immune Tolerance | 1 | 1990 | 158 | 0.000 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 1990 | 178 | 0.000 |
Why?
|
| Population Surveillance | 1 | 1970 | 418 | 0.000 |
Why?
|
| Sciatic Nerve | 1 | 1987 | 64 | 0.000 |
Why?
|
| Frontal Lobe | 1 | 1988 | 122 | 0.000 |
Why?
|
| Drug Therapy, Combination | 1 | 1991 | 1197 | 0.000 |
Why?
|
| Neoplasm Invasiveness | 1 | 1987 | 667 | 0.000 |
Why?
|
| Graft vs Host Disease | 1 | 1990 | 623 | 0.000 |
Why?
|
| Incidence | 1 | 1990 | 3393 | 0.000 |
Why?
|
| Inflammation | 1 | 1990 | 1599 | 0.000 |
Why?
|
| Time Factors | 1 | 1988 | 6588 | 0.000 |
Why?
|
| Florida | 1 | 1970 | 79 | 0.000 |
Why?
|
| Hemagglutination Inhibition Tests | 1 | 1970 | 115 | 0.000 |
Why?
|
| Serologic Tests | 1 | 1970 | 131 | 0.000 |
Why?
|